Sanofi's venglustat fails another trial, ending pursuit of kidney disease | Fierce Biotech
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Ibiglustat (L-Malic acid) (Venglustat (L-Malic acid)) | Glucosylceramide Synthase Inhibitor | MedChemExpress
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
IJMS | Free Full-Text | Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
Sanofi halts venglustat clinical programme in kidney disease
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
%20for%20Fabry%20Disease.png?md=1 "Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power")
Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Genes | Free Full-Text | The Genetics of Parkinson's Disease and Implications for Clinical Practice
Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. - Abstract - Europe PMC
Ziv Gan-Or on Twitter: "Despite being completely unclear whether glucosylceramide is relevant is PD, the plans for the trial continued as usual. Now, let's talk about some pre-clinical results, using mouse "PD
Venglustat | C20H24FN3O2S | CID 60199242 - PubChem
Gaucher Treatment Report
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial | Venglustat Led to Long-term Benefits in 5 of 6 Men in Phase 2 Trial | Fabry Disease News
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD - ScienceDirect
PERIDOT – Patient ExpeRIence in fabry Disease On venglustaT | M.A.G.I.C Clinic
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers - Peterschmitt - 2021 - Clinical Pharmacology in Drug Development - Wiley Online Library
